Safety concerns with the long-term management of osteoporosis

Denosumab-related osteonecrosis of the jaw

(2014) Pedro Diz et al.   JOURNAL OF THE AMERICAN DENTAL ASSOCIATION

Oral bisphosphonates are associated with increased risk of subtrochanteric and diaphyseal fractures in elderly women: a nested case–control study

(2013) Juan Erviti et al.   BMJ Open

Exposure to bisphosphonates and risk of gastrointestinal cancers: series of nested case-control studies with QResearch and CPRD data

(2013) Y. Vinogradova et al.   BMJ-British Medical Journal

Treatment of osteoporosis in men

(2012) J.-M. Kaufman et al.   BONE

Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF)

(2012) C. Cooper et al.   CURRENT MEDICAL RESEARCH AND OPINION

Atypical femoral fractures and bisphosphonate treatment

(2012) R. N. Thompson et al.   JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME

Reduced Risk of Colorectal Cancer With Use of Oral Bisphosphonates: A Systematic Review and Meta-Analysis

(2012) Nirav Thosani et al.   JOURNAL OF CLINICAL ONCOLOGY

Bisphosphonates for Osteoporosis — Where Do We Go from Here?

(2012) Marcea Whitaker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Continuing Bisphosphonate Treatment for Osteoporosis — For Whom and for How Long?

(2012) Dennis M. Black et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial

(2012) M. R. McClung et al.   OSTEOPOROSIS INTERNATIONAL

Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications

(2012) J.-J. Body et al.   OSTEOPOROSIS INTERNATIONAL

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

(2012) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

Occurrence of Gastrointestinal Cancer in Users of Bisphosphonates and Other Antiresorptive Drugs Against Osteoporosis

(2011) Peter Vestergaard   CALCIFIED TISSUE INTERNATIONAL

Adverse Reactions and Drug–Drug Interactions in the Management of Women with Postmenopausal Osteoporosis

(2011) René Rizzoli et al.   CALCIFIED TISSUE INTERNATIONAL

Use of Bisphosphonates and Risk of Breast Cancer

(2011) Peter Vestergaard et al.   CALCIFIED TISSUE INTERNATIONAL

What is the optimal duration of bisphosphonate therapy?

(2011) S. M. OTT   CLEVELAND CLINIC JOURNAL OF MEDICINE

Atrial fibrillation and bisphosphonate therapy

(2011) Michael Pazianas et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension

(2011) Socrates Papapoulos et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Esophageal and gastric cancer incidence and mortality in alendronate users

(2011) Bo Abrahamsen et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

(2011) Dennis M Black et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Evolution of bisphosphonate-related atypical fracture retrospectively observed with DXA scanning

(2011) Mark A Ahlman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Teriparatide, Vitamin D, and Calcium Healed Bilateral Subtrochanteric Stress Fractures in a Postmenopausal Woman with a 13-Year History of Continuous Alendronate Therapy

(2011) Stephen J. Gomberg et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Atypical Femoral Fractures during Prolonged Use of Bisphosphonates: Short-Term Responses to Strontium Ranelate and Teriparatide

(2011) N. N. C. Carvalho et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Oral Bisphosphonate Use Increases the Risk for Inflammatory Jaw Disease: A Cohort Study

(2011) Peter Vestergaard et al.   JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY

Bisphosphonate Use and Atypical Fractures of the Femoral Shaft

(2011) Jörg Schilcher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis

(2011) J-Y. Reginster et al.   OSTEOPOROSIS INTERNATIONAL

Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?

(2011) N. B. Watts et al.   OSTEOPOROSIS INTERNATIONAL

Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study

(2011) S. L. Silverman et al.   OSTEOPOROSIS INTERNATIONAL

Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis

(2011) Barry S. Komm et al.   Therapeutic Advances in Musculoskeletal Disease

Impact of Bisphosphonates on the Risk of Atrial Fibrillation

(2010) Patricia A. Howard et al.   American Journal of Cardiovascular Drugs

Risk of Atrial Fibrillation Associated with Use of Bisphosphonates and Other Drugs Against Osteoporosis: A Cohort Study

(2010) Peter Vestergaard et al.   CALCIFIED TISSUE INTERNATIONAL

Impact of Treatments for Postmenopausal Osteoporosis (Bisphosphonates, Parathyroid Hormone, Strontium Ranelate, and Denosumab) on Bone Quality: A Systematic Review

(2010) S. J. Gallacher et al.   CALCIFIED TISSUE INTERNATIONAL

Incidence of Venous Thromboembolism in Users of Strontium Ranelate

(2010) Vicki Osborne et al.   DRUG SAFETY

Exposure to Oral Bisphosphonates and Risk of Esophageal Cancer

(2010) Chris R. Cardwell et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases

(2010) O. Filleul et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis

(2010) Mark J. Bolland et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Cumulative Alendronate Dose and the Long-Term Absolute Risk of Subtrochanteric and Diaphyseal Femur Fractures: A Register-Based National Cohort Analysis

(2010) Bo Abrahamsen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Osteoporosis: impact on health and economics

(2010) Nicholas Harvey et al.   Nature Reviews Rheumatology

Lasofoxifene in Postmenopausal Women with Osteoporosis

(2010) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene

(2010) P. Vestergaard et al.   OSTEOPOROSIS INTERNATIONAL

Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report

(2010) R. Rizzoli et al.   OSTEOPOROSIS INTERNATIONAL

IOF position statement: vitamin D recommendations for older adults

(2010) B. Dawson-Hughes et al.   OSTEOPOROSIS INTERNATIONAL

Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial

(2010) T. J. de Villiers et al.   OSTEOPOROSIS INTERNATIONAL

Cutaneous Side Effects of Antiosteoporosis Treatments

(2010) Philippe Musette et al.   Therapeutic Advances in Musculoskeletal Disease

Osteonecrosis of the jaws induced by anti-RANK ligand therapy

(2009) K.H. Taylor et al.   BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY

Bisphosphonates in the Prevention of Disease Recurrence: Current Results and Ongoing Trials

(2009) M. Gnant   CURRENT CANCER DRUG TARGETS

Bisphosphonates and Atrial Fibrillation

(2009) Yoon Kong Loke et al.   DRUG SAFETY

Efficacy and Safety of Denosumab in Postmenopausal Women with Osteopenia or Osteoporosis: A Systematic Review and a Meta-analysis

(2009) A. D. Anastasilakis et al.   HORMONE AND METABOLIC RESEARCH

Reports of Esophageal Cancer with Oral Bisphosphonate Use

(2009) Diane K. Wysowski   NEW ENGLAND JOURNAL OF MEDICINE

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism

(2009) P. Vestergaard et al.   OSTEOPOROSIS INTERNATIONAL

Use of oral bisphosphonates and risk of venous thromboembolism: a population-based case-control study

(2009) A. L. Lamberg et al.   OSTEOPOROSIS INTERNATIONAL

Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab

(2009) K. A. Toulis et al.   OSTEOPOROSIS INTERNATIONAL

Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database

(2009) G. Breart et al.   OSTEOPOROSIS INTERNATIONAL

Use of Alendronate and Risk of Incident Atrial Fibrillation in Women

(2008) Susan R. Heckbert et al.   ARCHIVES OF INTERNAL MEDICINE

Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial

(2008) Jean-Yves Reginster et al.   ARTHRITIS AND RHEUMATISM

Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis

(2008) René Rizzoli et al.   BONE

Exploring the anti-tumour activity of bisphosphonates in early breast cancer

(2008) M.C. Winter et al.   CANCER TREATMENT REVIEWS

Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial*

(2008) Stuart L Silverman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Atypical Fractures of the Femoral Diaphysis in Postmenopausal Women Taking Alendronate

(2008) Brett A. Lenart et al.   NEW ENGLAND JOURNAL OF MEDICINE